Endpoints for clinical trials in oncology – Elisabeth de Vries (UMC Groningen, NL) – did not consent

Regulatory perspective (EU) – Aarón Sosa Mejía (DKMA, DK)

Regulatory perspective (US) – Nicole Gormley (FDA, US) – awaiting speaker consent

HTA perspective – Anja Schiel ( Nowrwegian Medicines Agency, NO)

Innovation in early phase trials – Christina Jap (Institute of Cancer Research, UK)

Innovation in late phase trials – Jan Bogaerts (EORTC, BE)

Estimands framework (regulatory perspective – Theodor Framke (EMA, NL)

Estimands ICH E9(R1) addendum – an industry perspective – Kaspar Rufibach (Roche, CH)

A patient perspective on evidence generation – Ana Amariutei (European Patient Advocacy Institute; WECAN, DE) – did not consent

Synthetic and external control arm – Laurence Collette (GSK, BE)

Project Pragmatica – Donna Rivera (FDA, US) – awaiting consent

Combinations – Alessandro Crotta (BMS, CH)

Studies on rare populations – Paolo Casali (EURACAN, IT)

Master protocol practicalities (industry perspective) – Brian Simmons (Roche, US) – did not consent

ICH guidance – Fergus Sweeney (Retire clinical trial expert, IE)